152 related articles for article (PubMed ID: 21385322)
1. Metabolism of ophthalmic timolol: new aspects of an old drug.
Volotinen M; Hakkola J; Pelkonen O; Vapaatalo H; Mäenpää J
Basic Clin Pharmacol Toxicol; 2011 May; 108(5):297-303. PubMed ID: 21385322
[TBL] [Abstract][Full Text] [Related]
2. Cardiac safety of ophthalmic timolol.
Mäenpää J; Pelkonen O
Expert Opin Drug Saf; 2016 Nov; 15(11):1549-1561. PubMed ID: 27534869
[TBL] [Abstract][Full Text] [Related]
3. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
Nieminen T; Lehtimäki T; Mäenpää J; Ropo A; Uusitalo H; Kähönen M
Scand J Clin Lab Invest; 2007; 67(2):237-45. PubMed ID: 17366003
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol.
Yang Y; Wu K; Yuan H; Yu M
J Ocul Pharmacol Ther; 2009 Apr; 25(2):163-71. PubMed ID: 19284319
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Ocular Bioactivation Potential and the Role of Cytochrome P450 2D Enzymes in Rat.
Dumouchel JL; Argikar UA; Spear J; Brown A; Dunne CE; Kramlinger VM; Cirello AL; Gunduz M
Drug Metab Lett; 2017; 11(2):102-110. PubMed ID: 28891437
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
Edeki TI; He H; Wood AJ
JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma--a pilot study.
Yuan H; Yu M; Yang Y; Wu K; Lin X; Li J
J Ocul Pharmacol Ther; 2010 Oct; 26(5):497-501. PubMed ID: 20925579
[TBL] [Abstract][Full Text] [Related]
9. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
Mäenpää J; Volotinen-Maja M; Kautiainen H; Neuvonen M; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
[TBL] [Abstract][Full Text] [Related]
10. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
Tan AY; LeVatte TL; Archibald ML; Tremblay F; Kelly ME; Chauhan BC
J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
[TBL] [Abstract][Full Text] [Related]
11. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.
Ishii Y; Nakamura K; Tsutsumi K; Kotegawa T; Nakano S; Nakatsuka K
J Clin Pharmacol; 2000 Feb; 40(2):193-9. PubMed ID: 10664926
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical and pharmacological investigation of water/oil microemulsion of non-selective beta blocker for treatment of glaucoma.
Hegde RR; Bhattacharya SS; Verma A; Ghosh A
Curr Eye Res; 2014 Feb; 39(2):155-63. PubMed ID: 24073659
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes.
Chiang CH; Ho JI; Chen JL
J Ocul Pharmacol Ther; 1996; 12(4):471-80. PubMed ID: 8951683
[TBL] [Abstract][Full Text] [Related]
14. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
Korte JM; Kaila T; Saari KM
Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
Ishii Y; Nakamura K; Matsuki S; Uemura N; Muraguchi R; Nakagawa M; Nakano S; Nakatsuka K
J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
[TBL] [Abstract][Full Text] [Related]
17. Beta-adrenergic glaucoma drugs reduce lymphatic clearance from the eye: A sequential photoacoustic imaging study.
Hanna J; Yücel YH; Zhou X; Kim N; Irving H; Gupta N
Exp Eye Res; 2021 Nov; 212():108775. PubMed ID: 34599970
[TBL] [Abstract][Full Text] [Related]
18. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma.
Ergin A; Ornek K; Güllü R; Bulcun E; Ekici M; Ekici A
J Ocul Pharmacol Ther; 2009 Oct; 25(5):463-6. PubMed ID: 19552600
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ophthalmic beta-blocking agents.
Lesar TS
Clin Pharm; 1987 Jun; 6(6):451-63. PubMed ID: 2891463
[TBL] [Abstract][Full Text] [Related]
20. Effects of topically applied falintolol: a new beta-adrenergic antagonist for treatment of glaucoma.
Himber J; Sallee VL; Andermann G; Bouzoubaa M; Leclerc G; De Santis L
J Ocul Pharmacol; 1987; 3(2):111-20. PubMed ID: 2903204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
